Search results
Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
GuruFocus.com via Yahoo Finance Canada· 1 day agoFollowing this sale, the insider now owns 96,380 shares of Gilead Sciences Inc. Gilead Sciences Inc...
Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE?
Simply Wall St. via Yahoo Finance Canada· 24 hours agoWe'll use ROE to examine Gilead Sciences, Inc. (NASDAQ:GILD), by way of a worked example. ROE or...
Gilead Benefit Helps Employees Navigate Cancer Care
3BL CSRwire· 18 hours agoJim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human...
Should You Hold Gilead Sciences (GILD)?
Insider Monkey via Yahoo Finance Canada· 2 days agoParnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the...
Recent uptick might appease Gilead Sciences, Inc. (NASDAQ:GILD) institutional owners after losing...
Simply Wall St. via Yahoo Finance Canada· 7 days agoKey Insights Institutions' substantial holdings in Gilead Sciences implies that they have...
HIV breakthrough: drug trial shows injection twice a year is 100% effective against infection
The Conversation· 6 hours agoA large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection. The trial ...
Cancer Rates Surge: Key Biotech Stocks Leading the Charge in Oncology Drug Development
Baystreet· 6 days agoThe biotech sector is actively addressing this need, with recent notable developments from several companies, including: Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), GSK plc (NYSE: GSK ...
Game-Changing HIV Shot Can’t Get to High-Risk Groups Fast Enough
Bloomberg· 6 days agoLenacapavir proved it's possible to prevent 100% of infections in women. Lisa Jarvis is a Bloomberg...
The Corporate Reputation of Canadian Pharma, 2023-2024 - 100 Patient Groups Present their Views -...
Financial Post· 6 days agoDUBLIN — “The Corporate Reputation of Pharma in 2023/2024 – The Patient Perspective – Canada Edition – The Views of 100 Canadian Patient Groups” report has been added to ResearchAndMarkets.com ...
A Tech Reckoning Is Coming, Financial Pro Says. It’s Time to Play Defense.
Barrons.com· 5 days agoSpecifically, Bahnsen points to specific stocks such as American Electric Power Gilead Sciences and...